Y-27632 Dihydrochloride: Selective ROCK1/2 Inhibitor for Cell and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a potent, small-molecule inhibitor that selectively targets ROCK1 and ROCK2, with an IC50 of 140 nM for ROCK1 and Ki of 300 nM for ROCK2, showing >200-fold selectivity over other kinases (ApexBio). It disrupts Rho-mediated stress fiber formation and modulates cell cycle progression and cytokinesis (Ni et al., 2022). In cell culture, Y-27632 enhances stem cell viability and survival, facilitating robust iPSC and organoid generation. In vivo, it suppresses tumor invasion and metastasis in mouse models. The compound's solubility and stability parameters enable reliable integration into diverse experimental workflows.

Biological Rationale

Y-27632 dihydrochloride is designed to modulate the Rho/ROCK signaling pathway, which regulates cytoskeletal organization, cell migration, and proliferation. ROCK1 and ROCK2 are serine/threonine kinases activated downstream of RhoA. Their activity is implicated in cellular processes such as stress fiber assembly, focal adhesion formation, and smooth muscle contraction (Ni et al., 2022). Inhibition of ROCK signaling is a validated approach to attenuate abnormal cytoskeletal dynamics observed in cancer, fibrosis, and neurological disease models.

Induced pluripotent stem cells (iPSCs), which are sensitive to dissociation-induced apoptosis, benefit from ROCK inhibition for survival and expansion, enabling robust stem cell research and disease modeling (Ni et al., 2022).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride selectively binds to the catalytic domain of ROCK1 and ROCK2, competitively inhibiting ATP binding. This leads to potent suppression of ROCK kinase activity, with measured IC50 values of approximately 140 nM for ROCK1 and Ki of 300 nM for ROCK2 (ApexBio). Selectivity assays demonstrate >200-fold specificity against other kinases, including PKC, cAMP-dependent protein kinase, MLCK, and PAK (GDC-0879).

By inhibiting ROCK, Y-27632 disrupts downstream phosphorylation of myosin light chain (MLC) and LIM kinase substrates, blocking actin-myosin contractility and stress fiber formation. This results in altered cell morphology, reduced cellular tension, and increased cell survival during mechanical stress or dissociation (Ni et al., 2022). The compound also interferes with G1/S phase cell cycle progression and inhibits cytokinesis, further impacting proliferation and tissue architecture.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC50 of 140 nM and ROCK2 with a Ki of 300 nM, demonstrating >200-fold selectivity versus PKC and PKA (ApexBio).
• Enhances survival and expansion of human iPSC cultures by inhibiting dissociation-induced apoptosis (Ni et al., 2022).
• Reduces stress fiber formation and cellular contractility in prostatic smooth muscle and cancer cells in vitro (Fam-Azide-5-Isomer).
• Suppresses tumor invasion and metastasis in mouse xenograft models of cancer (Beta-Sheet-Breaker-Peptide-IA-5).
• Y-27632 is highly soluble in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), and water (≥52.9 mg/mL), supporting a range of experimental conditions (ApexBio).
• Storage at <-20°C preserves stock solutions for several months, but long-term solution storage is discouraged due to potential degradation (ApexBio).

This article extends prior reviews such as GDC-0879 by providing more granular solubility and selectivity data, and contrasts with Beta-Sheet-Breaker-Peptide-IA-5 by focusing on standardized benchmarks relevant for reproducible workflows.

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is broadly used to:

• Enhance stem cell viability and proliferation, especially for iPSC and ESC cultures (Ni et al., 2022).
• Facilitate single-cell passaging and organoid generation.
• Study cytoskeletal dynamics, cell migration, and wound healing assays.
• Suppress tumor invasion and metastasis in preclinical animal models.
• Dissect Rho/ROCK pathway functions in cancer, fibrosis, and neurobiology.

However, its high selectivity for ROCK1/2 means it does not broadly inhibit all kinases involved in cytoskeletal regulation. For example, MLCK, PKC, and PAK are unaffected at concentrations effective for ROCK inhibition (ApexBio).

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: Y-27632 does not inhibit PKC, PKA, MLCK, or PAK at research-grade concentrations; its effects are specific to ROCK1/2.
• Not cytotoxic at recommended doses: While it modulates cell proliferation, Y-27632 does not induce apoptosis in most cell types at standard working concentrations (1–10 μM).
• Not stable in solution long-term: Stock solutions should be stored at <-20°C and used within a few months; avoid repeated freeze-thaw cycles.
• Not a substitute for all cytoskeletal modulators: For actin stabilization or microtubule targeting, alternative agents are required.
• Does not replace genetic ROCK knockdown: Phenotypes may differ between pharmacological and genetic inhibition due to compensatory mechanisms.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid and should be stored desiccated at 4°C or lower (ApexBio). For use, dissolve to ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. Warming to 37°C or ultrasonic bath can aid solubilization. Recommended working concentrations are 1–10 μM for cell culture. Prepare aliquots to minimize freeze-thaw cycles, and avoid storing diluted solutions long-term.

In stem cell and organoid workflows, Y-27632 is typically added during cell dissociation and early recovery phases to enhance viability. In cancer models, pre-treatment or co-treatment can reduce invasion and metastasis phenotypes (Fam-Azide-5-Isomer). For in vivo use, dosing regimens must be optimized based on animal model and route of administration.

For further practical guidance, see the extended protocols in MorangemRNA, which provides detailed workflow integration for cytoskeletal, stem cell, and tumor biology applications. This article updates those protocols with new solubility and storage parameters.

Conclusion & Outlook

Y-27632 dihydrochloride is a gold-standard, cell-permeable ROCK inhibitor enabling reproducible modulation of the Rho/ROCK pathway in cell biology, cancer, and regenerative research. Its high potency, selectivity, and well-defined solubility/storage properties support robust assay development and translational studies. While it is not a substitute for genetic approaches or non-ROCK cytoskeletal modulators, Y-27632 remains indispensable for stem cell survival, organoid generation, and anti-invasion studies. For ordering and product specifications, refer to the Y-27632 dihydrochloride A3008 kit at ApexBio.